Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.042
EU - Europa 2.382
AS - Asia 868
AF - Africa 26
SA - Sud America 15
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 11.342
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.035
IT - Italia 655
FI - Finlandia 557
CN - Cina 492
DE - Germania 281
SG - Singapore 230
UA - Ucraina 205
IE - Irlanda 157
GB - Regno Unito 134
SE - Svezia 112
RU - Federazione Russa 89
RO - Romania 54
BE - Belgio 47
FR - Francia 45
IN - India 40
TR - Turchia 29
CI - Costa d'Avorio 25
KR - Corea 22
IR - Iran 15
CH - Svizzera 10
ES - Italia 8
HK - Hong Kong 8
NL - Olanda 8
UZ - Uzbekistan 7
PL - Polonia 6
BR - Brasile 5
CA - Canada 5
EU - Europa 5
CL - Cile 4
LB - Libano 4
CZ - Repubblica Ceca 3
IL - Israele 3
JP - Giappone 3
KZ - Kazakistan 3
TW - Taiwan 3
AR - Argentina 2
AU - Australia 2
CO - Colombia 2
GR - Grecia 2
ID - Indonesia 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
EE - Estonia 1
JM - Giamaica 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MC - Monaco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
VN - Vietnam 1
Totale 11.342
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 781
Woodbridge 765
Wilmington 575
Chandler 572
Seattle 570
Houston 529
Cambridge 526
Ann Arbor 494
Singapore 174
Palermo 168
Dublin 155
Medford 141
Des Moines 122
Altamura 118
Nanjing 109
Jacksonville 107
Princeton 90
Lawrence 80
San Diego 71
Santa Clara 63
Beijing 54
Boardman 53
Dearborn 50
New York 50
Brussels 46
Tulsa 41
Ludwigshafen am Rhein 39
Changsha 36
London 33
Nanchang 33
Shenyang 33
Phoenix 32
Hebei 29
Jiaxing 28
Bremen 27
Abidjan 25
Izmir 25
Tianjin 25
Jinan 22
Kitzingen 22
Helsinki 21
Kumar 21
Saint Petersburg 20
Seongnam 20
Zhengzhou 18
Milan 16
Ningbo 16
San Paolo di Civitate 15
Hangzhou 12
Venice 12
Washington 12
Chicago 11
Los Angeles 11
Berlin 10
Guangzhou 10
Tehran 9
Munich 8
Norwalk 8
Pune 8
Rome 8
Verona 8
Frankfurt am Main 7
Hong Kong 7
Kilburn 7
Taiyuan 6
Auburn Hills 5
Frankfurt Am Main 5
Fuzhou 5
Hanover 5
Kunming 5
Orange 5
San Mateo 5
Cagliari 4
Indiana 4
Islington 4
Moscow 4
Mountain View 4
Redmond 4
Redwood City 4
St Petersburg 4
Taizhou 4
Tappahannock 4
Zurich 4
Chengdu 3
Detroit 3
Haikou 3
Hefei 3
Marano di Napoli 3
Montepulciano 3
Napoli 3
New Delhi 3
Nürnberg 3
San Francisco 3
Shanghai 3
Taipei 3
Vigliano Biellese 3
Walnut 3
Wandsworth 3
Amsterdam 2
Totale 8.779
Salva come PNG Salva come JPEG
Nome #
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 212
Dietary restriction: could it be considered as speed bump on tumor progression road? 211
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 200
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 195
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 191
Anti-endothelin drugs in solid tumors 177
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 175
EGFR genomic alterations in cancer: prognostic and predictive values 175
A headlight on liquid biopsies: a challenging tool for breast cancer management 175
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 174
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 172
HER2-positive male breast cancer: An update 168
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 168
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 166
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 163
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 162
Nintedanib in NSCLC: Evidence to date and place in therapy 162
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 161
Targeted Therapies in Hepatocellular Carcinoma 161
Monoclonal antibodies in gastrointestinal cancers 161
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 160
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 159
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 158
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 153
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 152
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 152
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 150
The role of targeted therapy for gastrointestinal tumors 149
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 148
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 148
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 148
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 148
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 148
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 148
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 148
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 146
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 144
Multisciplinary management of patients with liver metastasis from colorectal cancer 143
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 141
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 141
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 140
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 139
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 139
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 138
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 138
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 138
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 138
Sex steroids, carcinogenesis, and cancer progression 138
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 132
Cancer and the microbiome: Potential applications as new tumor biomarker 132
Well-being among Italian medical oncologists: An exploratory study 130
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 129
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 129
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 129
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 129
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 128
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 127
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 127
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 125
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 118
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 117
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 115
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 115
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 114
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 113
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 111
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 109
Bortezomib: a new pro-apoptotic agent in cancer treatment. 107
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 107
Ramucirumab and its use in gastric cancer treatment 106
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 104
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 99
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 94
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 93
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 89
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 88
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 86
Apoptosis in Thyroid Autoimunity. 82
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 82
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 77
VIPoma and PPoma 76
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 73
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 72
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 71
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 66
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 65
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 64
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 63
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 52
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 42
Totale 11.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.790 0 0 0 635 401 392 323 266 291 187 210 85
2020/20211.493 117 82 88 130 85 32 124 118 162 224 159 172
2021/20221.317 58 284 72 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024666 29 87 51 51 47 132 64 86 7 10 9 93
2024/2025417 25 151 184 57 0 0 0 0 0 0 0 0
Totale 11.808